Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation

Edy Meiyanto ^1,2 * , Herwandhani Putri ², Yonika Arum Larasati ² , Rohmad Yudi Utomo ^1,2 , Riris Istighfari Jenie ¹ , Muthi Ikawati ¹ , Beni Lestari ^2,3 , Noriko Yoneda-Kato ³, Ikuko Nakamae ³, Masashi Kawaichi ⁴, Jun-Ya Kato ³

Cited by CrossRef: 24

1- Schmidt B, Ferreira C, Alves Passos C, Silva J, Fialho E. Resveratrol, Curcumin and Piperine Alter Human Glyoxalase 1 in MCF-7 Breast Cancer Cells. IJMS. 2020;21(15):5244 [Crossref]

2- Wang C, Dong L, Li X, Li Y, Zhang B, Wu H, Shen B, Ma P, Li Z, Xu Y, Chen B, Pan S, Fu Y, Huo Z, Jiang H, Wu Y, Ma Y. The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma. Free Radical Biology and Medicine. 2021;163:141 [Crossref]

3- Javed Z, Khan K, Rasheed A, Sadia H, Shahwani M, Irshad A, Raza S, Salehi B, Sharifi-Rad J, Suleria H, Cruz-Martins N, Quispe C. Targeting androgen receptor signaling with MicroRNAs and Curcumin: a promising therapeutic approach for Prostate Cancer Prevention and intervention. Cancer Cell Int. 2021;21(1) [Crossref]

4- Wang J, Yang X, Wang Z, Wang J. Role of the Glyoxalase System in Breast Cancer and Gynecological Cancer-Implications for Therapeutic Intervention: a Review. Front Oncol. 2022;12 [Crossref]

5- Novitasari D, Jenie R, Kato J, Meiyanto E. The integrative bioinformatic analysis deciphers the predicted molecular target gene and pathway from curcumin derivative CCA-1.1 against triple-negative breast cancer (TNBC). J Egypt Natl Canc Inst. 2021;33(1) [Crossref]

6- Ballester P, Cerdá B, Arcusa R, García-Muñoz A, Marhuenda J, Zafrilla P. Antioxidant Activity in Extracts from Zingiberaceae Family: Cardamom, Turmeric, and Ginger. Molecules. 2023;28(10):4024 [Crossref]

7- Hermawan A, Putri H. Systematic analysis of potential targets of the curcumin analog pentagamavunon-1 (PGV-1) in overcoming resistance of glioblastoma cells to bevacizumab. Saudi Pharmaceutical Journal. 2021;29(11):1289 [Crossref]

8- Ming T, Tao Q, Tang S, Zhao H, Yang H, Liu M, Ren S, Xu H. Curcumin: An epigenetic regulator and its application in cancer. Biomedicine & Pharmacotherapy. 2022;156:113956 [Crossref]

9- Janda E, Nepveu F, Calamini B, Ferry G, Boutin J. Molecular Pharmacology of NRH:Quinone Oxidoreductase 2: A Detoxifying Enzyme Acting as an Undercover Toxifying Enzyme. Mol Pharmacol. 2020;98(5):620 [Crossref]

10- Liu Y, Xiang D, Zhang H, Yao H, Wang Y, Barreto E. Hypoxia-Inducible Factor-1: A Potential Target to Treat Acute Lung Injury. Oxidative Medicine and Cellular Longevity. 2020;2020:1 [Crossref]

11- Wu M, Deng C, Lo T, Chan K, Li X, Wong C. Peroxiredoxin, Senescence, and Cancer. Cells. 2022;11(11):1772 [Crossref]

12- Yu C, Yang B, Najafi M. Targeting of cancer cell death mechanisms by curcumin: Implications to cancer therapy. Basic Clin Pharma Tox. 2021;129(6):397 [Crossref]

13- Endah E, Wulandari F, Putri Y, Jenie R, Meiyanto E. Piperine Increases Pentagamavunon-1 Anti-cancer Activity on 4T1 Breast Cancer Through Mitotic Catastrophe Mechanism and Senescence with Sharing Targeting on Mitotic Regulatory Proteins. Iran J Pharm Res. 2022;21(1) [Crossref]

14- Flint A, Hansen D, Brown L, Stewart L, Ortiz E, Panda S. Modified Curcumins as Potential Drug Candidates for Breast Cancer: An Overview. Molecules. 2022;27(24):8891 [Crossref]

15- Hariono M, Nuwarda R, Yusuf M, Rollando R, Jenie R, Al-Najjar B, Julianus J, Putra K, Nugroho E, Wisnumurti Y, Dewa S, Jati B, Tiara R, Ramadani R, Qodria L, Wahab H. Arylamide as Potential Selective Inhibitor for Matrix Metalloproteinase 9 (MMP9): Design, Synthesis, Biological Evaluation, and Molecular Modeling. J Chem Inf Model. 2020;60(1):349 [Crossref]

16- Kamitani N, Nakamae I, Yoneda-Kato N, Kato J, Sho M. Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models. Sci Rep. 2022;12(1) [Crossref]

17- Wulandari F, Ikawati M, Meiyanto E, Kirihata M, Hermawan A. Bioinformatic analysis of CCA-1.1, a novel curcumin analog, uncovers furthermost noticeable target genes in colon cancer. Gene Reports. 2020;21:100917 [Crossref]

18- Novitasari D, Jenie R, Wulandari F, Utomo R, Pamungkas Putri D, Kato J, Meiyanto E. Curcumin-like structure (CCA-1.1) induces permanent mitotic arrest (Senescence) on Triple-negative breast cancer (TNBC) cells, 4T1. RJPT. 2021;:4375 [Crossref]

19- Sanlier N, Kocabas Ş, Erdogan K, Sanlier N. Effects of curcumin, its analogues, and metabolites on various cancers: focusing on potential mechanisms. Food Reviews International. 2023;39(8):5356 [Crossref]

20- Hasbiyani N, Wulandari F, Nugroho E, Hermawan A, Meiyanto E. Bioinformatics Analysis Confirms the Target Protein Underlying Mitotic Catastrophe of 4T1 Cells under Combinatorial Treatment of PGV-1 and Galangin. Sci Pharm. 2021;89(3):38 [Crossref]

21- Novitasari D, Nakamae I, Istighfari Jenie R, Yoneda-Kato N, Kato J, Meiyanto E. Pentagamavunone-1 inhibits aggressive breast cancer cell proliferation through mitotic catastrophe and ROS-mediated activities: in vitro and in vivo studies. Saudi Pharmaceutical Journal. 2024;32(1):101892 [Crossref]

22- Utomo R, Wulandari F, Novitasari D, Lestari B, Susidarti R, Jenie R, Kato J, Sardjiman S, Meiyanto E. Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties. Adv Pharm Bull. 2022;12(3):603 [Crossref]

23- Zulfin U, Rahman A, Hanifa M, Utomo R, Haryanti S, Meiyanto E. Reactive oxygen species and senescence modulatory effects of rice bran extract on 4T1 and NIH-3T3 cells co-treatment with doxorubicin. Asian Pac J Trop Biomed. 2021;11(4):174 [Crossref]